A double-blind, placebo-controlled single dose trial of intravenous flumazenil in Alzheimer's disease

Human Psychopharmacology

Volumn 14, Issue 4, 1999, Pages 239-245

  Templeton, Lisa ^a   Barker, Andrew ^b   Wesnes, Keith ^c   Wilkinson, David ^d  

^a ROYAL HAMPSHIRE COUNTY HOSPITAL   (United Kingdom)

^b Ringwood CMHT   (United Kingdom)

^c CDR House ^*  (United Kingdom)

^d MOORGREEN HOSPITAL   (United Kingdom)

Author keywords

Alzheimer's disease; Benzodiazepine antagonists; Cognitive function; Dementia; Flumazenil; Reaction time

Indexed keywords

BENZODIAZEPINE RECEPTOR BLOCKING AGENT; FLUMAZENIL;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; REACTION TIME;

EID: 0032973812     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1077(199906)14:4<239::AID-HUP94>3.0.CO;2-R     Document Type: Article

References (28)

1. Bishop, K. I. and Curran, H. V. (1995). Psychopharmacological analysis of implicit and explicit memory: a study with lorazepam and the benzodiazepine antagonist flumazenil. Psychopharmacology, 121, 267-278.
2. Breimer, L. T. M., Hennis, P. J., Burm, A. G. L., Danhof, M., Bovill, J. G., Spierdijk, J. and Vletter, A. A. (1991). Pharmacokinetics and EEG effects of flumazenil in volunteers. Clinical Pharmocokinetics, 20, 491-496.
3. Brogden, R. N. and Goa, K. L. (1991). Flumazenil: a reappraisal of its pharmacological properties and therapeutic efficacy as a benzodiazepine antagonist. Drugs, 42, 1061-1089.
4. Carlson, M. D., Penney, J. B. Jr and Young, A. B. (1993). NMDA, AMPA and benzodiazepine binding site changes in Alzheimer's Disease visual cortex. Neurobiology of Ageing, 14(4), 343-352.
5. Duka, T. and Dorow, R. (1995). Human experimental psychopharmacology of benzodiazepine receptor inverse agonists and antagonists. In Benzodiazepine Receptor Inverse Agonists, Wiley-Liss, pp. 243-270.
6. Duka, T., Redemann, B., Mager, T. and Voet, B. (1993). Scopolamine as a pharmacological tool to study memory processes: application of a cognitive enhancer. Society of Neuroscience Abstracts, 19, 507.5.
7. Folstein, M. F., Folstein, S. E. and McHugh, P. R. (1975). "Mini-Mental State" - a practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12, 189-198.
8. Frey, P. W. and Colliver, J. A. (1973). Sensitivity and response measures for discrimination learning. Learning and Motivation, 4, 327-342.
9. Ghoneim, M. D., Block, R. I., Sum Ping, S. T., ElZahaby, H. M. and Hinrichs, J. V. (1993). The interactions of midazolam and flumazenil on human memory and cognition. Anesthesiology, 79, 1183-1192.
10. A receptor modulation of memory: the role of endogenous benzodiazepines. Trends in Pharmacological Sciences, 12, 260-265.
11. Jones, E. A., Basile, A. S., Yurdaydin, C. and Skolnich, P. (1994). Do benzodiazepine ligands contribute to hepatic encephalopathy? In Cirrhosis, Hyperammonemia and Hepatic Encephalopathy, Grisola, S. and Felipo, V. (Eds), Plenum Press, New York.
12. Knapp, M. J., Knopman, D. S., Solomon, P. R., Pendelbury, W. W., Davis, C. S. and Gracon, S. I. (1994). A 30-week randomised controlled trial of high-dose Tacrine in patients with Alzheimer's disease. Journal of the American Medical Association, 271, 985-991.
13. McKhann, G., Drachman, D., Folstein, M., Price, D. and Stadlan, E. (1984). Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology, 34, 939-944.
14. Meyer, M., Koeppe, R. A., Frey, K. A., Foster, N. L. and Kuhl, D. E. (1995). Positron emission tomography measures of benzodiazepine binding in Alzheimer's Disease. Archives of Neurology, 52, 314-317.
15. Nutt, D. J., Glue, P., Lawson, C. and Wilson, S. (1990). Flumazenil provocation of panic attacks. Archives of General Psychiatry, 47, 917-925.
16. Ott, B. R., Thompson, J. A. and Whelihan, W. M. (1996). Cognitive effects of flumazenil in patients iwth Alzheimer's Disease. Journal of Clinical Psychopharmacology, 16, 400-402.
17. Persson, A., Ehrin, E., Eriksson, L., Farde, L., Hedstrom, C.-G., Litton, J.-E., Mindus, P. and Sedval, G. (1985). Imaging of (14C)-labelled Ro 15-1788 binding to benzodiazepine receptors in the human brain by positron emission tomography. Journal of Psychiatric Research, 19, 609-622.
18. Pomara, N., Stanley, B., Block, R., Guido, J., Russ, D., Berchou, R., Stanley, M., Greenblatt, D. J. and Newton, R. E. (1984). Adverse effects of single therapeutic doses of diazepam on performance in normal geriatric subjects: relationship to plasma concentrations. Psychopharmacology, 84, 342-346.
19. Preston, G. C., Broks, P., Traub, M., Ward, C., Poppleton, P. and Stahl, S. M. (1988). Effects of lorazepam on memory, attention and sedation in man. Psychopharmacology, 95, 208-215.
20. Rogers, S. L., Friedhoff, L. T. and the Donepezil Study Group (1996). The efficacy and safety of donepezil in patients with Alzheimer's Disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia, 7, 293-303.
21. Rusted, J. M., Eaton-Williams, P. and Warburton, D. M. (1991). A comparison of the effects of scopolamine and diazepam on working memory. Psychopharmacology, 105, 442-445.
22. Sarter, M. (1994). Neronal mechanisms of the attentional dysfunctions in senile dementia and schizophrenia: two sides of the same coin? Psychopharmacology, 114, 539-550.
23. Sarter, M., Bruno, J. P. and Dudchenko, P. (1990). Activating the damaged basal forebrain cholinergic system: tonic stimulation versus signal amplification. Psychopharmacology, 101, 1-17.
24. Shimohama, S., Taniguchi, T., Fujiwara, M. and Kamcyama, M. (1988). Changes in benzodiazepine receptors in Alzheimer-type dementia. Annals of Neurology, 23(4), 404-406.
25. Simpson, P. M., Surmon, D. J., Wesnesm K. A. and Wilcock, G. K. (1991). The cognitive drug research computerized assessment system for demented patients: a validation study. International Journal of Geriatric Psychiatry, 6, 95-102.
26. Sunderland, T, Weingartner, H., Cohen, R., Tariot, P. N., Newhouse, P. A., Thompson, K. E., Lawlor, B. A. and Mueller, E. A. (1989). Low-dose oral lorazepam administration in Alzheimer subjects and age-matched controls. Psychopharmacology, 99, 129-133.
27. Watkins, P. B., Zimmerman, H. J., Knapp, M. J., Gracon, S. I. and Lewis, K. W. (1994). Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. Journal of the American Medical Association, 271, 992-998.
28. Wesnes, K., Simpson, P. and Kidd, A. (1987). The use of a scopolamine model to study the nootropic effects of tenilsetam in man. Medical Science Research, 15, 1063-1064.